699800 | MPLA (PHAD®)
Monophosphoryl Lipid A (Synthetic) (PHAD®)
MPLA (PHAD®)
Monophosphoryl Lipid A (Synthetic) (PHAD®)
PHAD® is a synthetic structural analog of monophosphoryl Lipid A (MPLA) that has been shown to boost the immune system through activation of the toll-like receptor 4 (TLR4) resulting in production of proinflammatory cytokines and antigen-specific effector CD4+ and memory CD8+ T cells. Also referred to as GLA, this adjuvant has been administered to well over 1000 human subjects without serious adverse events. PHAD® is available in bulk quantities for vaccine development and commercial manufacturing.
Stimulatory effect of PHAD®, 3D-PHAD®, and 3D(6-acyl)-PHAD® on macrophages. Macrophage cell line J774 cells were cultured with Avanti PHAD®, 3D-PHAD®, or 3D(6-acyl)-PHAD® for 24hrs. IL-12 levels in supernatants were measured by sandwich ELISA.
Adjuvant Activity
PHAD®, 3D-PHAD®, and 3D(6A)-PHAD® have been tested extensively in animals using a variety of antigens. In all cases, these adjuvants exhibit a similar activity and safety profile to bacterially-derived MPL. The data above demonstrate the equivalency of the three synthetic adjuvants to the bacterially-derived MPL when presented in a liposomal carrier system (DMPC/DMPG/Cholesterol).
- ChemDraw File
- 3D Structure
- Structure
- Brochure
- 699800 Adjuvant Data
- Safety Data Sheet
Fisher BS, Dambrauskas N, Trakhimets O, Andrade DV, Smedley J, Sodora DL, Sather DN. Oral Immunization with HIV-1 Envelope SOSIP trimers elicits systemic immune responses and cross-reactive anti-V1V2 antibodies in non-human primates. PLoS One. 2020 May 29;15(5):e0233577. doi: 10.1371/journal.pone.0233577. PMID: 32470041; PMCID: PMC7259690.
PubMed ID: 32470041Richard K, Perkins DJ, Harberts EM, Song Y, Gopalakrishnan A, Shirey KA, Lai W, Vlk A, Mahurkar A, Nallar S, Hawkins LD, Ernst RK, Vogel SN. Dissociation of TRIF bias and adjuvanticity. Vaccine. 2020 Jun 2;38(27):4298-4308. doi: 10.1016/j.vaccine.2020.04.042. Epub 2020 May 7. PMID: 32389496; PMCID: PMC7302928.
PubMed ID: 32389496Boudousquié C, Boand V, Lingre E, Dutoit L, Balint K, Danilo M, Harari A, Gannon PO, Kandalaft LE. Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine. Vaccines (Basel). 2020 Jan 14;8(1):E25. doi: 10.3390/vaccines8010025. PMID: 31947581.
PubMed ID: 31947581Verma A, Schmidt BA, Elizaldi SR, Nguyen NK, Walter KA, Beck Z, Trinh HV, Dinsarapu AR, Lakshmanappa YS, Rane NN, Matyas GR, Rao M, Shen X, Tomaras GD, LaBranche CC, Reimann KA, Foehl DH, Gach JS, Forthal DN, Kozlowski PA, Amara RR, Iyer SS. Impact of Th1 CD4 TFH skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. J Virol. 2019 Dec 11;JVI.01737-19. doi: 10.1128/JVI.01737-19. [Epub ahead of print]. PMID: 31827000.
PubMed ID: 31827000Wang L, Wang Z, Qin Y, Liang W. Delivered antigen peptides to resident CD8α+ DCs in lymph node by micelle-based vaccine augment antigen-specific CD8+ effector T cell response. Eur J Pharm Biopharm. 2020 Feb;147:76-86. doi: 10.1016/j.ejpb.2019.12.013. Epub 2019 Dec 28. PMID: 31887349.
PubMed ID: 31887349Hernandez A, Luan L, Stothers CL, Patil NK, Fults JB, Fensterheim BA, Guo Y, Wang J, Sherwood ER, Bohannon JK. Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens. Crit Care Med. 2019 Nov;47(11):e930-e938. doi: 10.1097/CCM.0000000000003967.
PubMed ID: 31567352Maynard S, Marshall JD, MacGill RS, Yu L, Cann JA, Cheng LI, McCarthy MP, Cayatte C, Robbins SH. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication. BMC Cancer. 2019 Jun 6;19(1):540. doi: 10.1186/s12885-019-5725-y.
PubMed ID: 31170937Belnoue E, Mayol JF, Carboni S, Di Berardino Besson W, Dupuychaffray E, Nelde A, Stevanovic S, Santiago-Raber ML, Walker PR, Derouazi M. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine. JCI Insight. 2019 Apr 23;5. pii: 127305. doi: 10.1172/jci.insight.127305.
PubMed ID: 31013258Zhao Z, Hu Y, Harmon T, Pentel P, Ehrich M, Zhang C. Effect of Adjuvant Release Rate on the Immunogenicity of Nanoparticle-Based Vaccines: A Case Study with a Nanoparticle-Based Nicotine Vaccine. Mol Pharm. 2019 Jun 3;16(6):2766-2775. doi: 10.1021/acs.molpharmaceut.9b00279. Epub 2019 May 22.
PubMed ID: 31075204Liang T, Leung LM, Opene B, Fondrie WE, Lee YI, Chandler CE, Yoon SH, Doi Y, Ernst RK, Goodlett DR. Rapid microbial identification and antibiotic resistance detection by mass spectrometric analysis of membrane lipids. Anal Chem. 2018 Dec 20. doi: 10.1021/acs.analchem.8b02611. [Epub ahead of print]
PubMed ID: 30571097Valencia S, Gill RB, Dowdell KC, Wang Y, Hornung R, Bowman JJ, Lacayo JC, Cohen JI. Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model. Vaccine. 2019 Jan 7;37(2):333-342. doi: 10.1016/j.vaccine.2018.08.043. Epub 2018 Dec 3.
PubMed ID: 30522906Jahan ST, Sadat SMA, Yarahmadi M, Haddadi A. Potentiating Antigen Specific Immune Response by Targeted Delivery of the PLGA-Based Model Cancer Vaccine. Mol Pharm. 2019 Feb 4;16(2):498-509. doi: 10.1021/acs.molpharmaceut.8b00700. Epub 2019 Jan 23.
PubMed ID: 30477303Liang T, Leung LM, Opene B, Fondrie WE, Lee YI, Chandler CE, Yoon SH, Doi Y, Ernst RK, Goodlett DR. Rapid microbial identification and antibiotic resistance detection by mass spectrometric analysis of membrane lipids. Anal Chem. 2018 Dec 20. doi: 10.1021/acs.analchem.8b02611. [Epub ahead of print]
PubMed ID: 30571097Lousada-Dietrich, S., Jogdand, P.S., Jepsen, S., Pinto, V.V., Ditlev, S.B., Christiansen, M., Larsen, S.O., Fox, C.B., Raman, V.S., Howard, R.F., Vedvick, T.S., Ireton, G., Carter, D., Reed, S.G., Theisen, M. (2011) A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - A GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine.
PubMed ID: 21349366Coler, R.N., Bertholet, S., Moutaftsi, M., Guderian, J.A., Windish, H.P., Baldwin, S.L., Laughlin, E.M., Duthie, M.S., Fox, C.B., Carter, D., Friede, M., Vedvick, T.S., Reed, S.G. (2011) Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One. 6:e16333.
PubMed ID: 21298114Anderson, R.C., Fox, C.B., Dutill, T.S., Shaverdian, N., Evers, T.L., Poshusta, G.R., Chesko, J., Coler, R.N., Friede, M., Reed, S.G., Vedvick, T.S. (2010) Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces. 75:123-32.
PubMed ID: 19748238Coler, R.N., S.L. Baldwin, N. Shaverdian, S. Bertholet, S.J. Reed, V.S. Raman, X. Lu, J. DeVos, K. Hancock, J.M. Katz, T.S. Vedvick, M.S. Duthie, C.H. Clegg, N. Van Hoeven, and S.G. Reed. (2010). A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 5:e13677.
PubMed ID: 21060869Fox, C.B., Friede, M., Reed, S.G., Ireton, G.C. (2010) Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem. 53:303-21
PubMed ID: 20593273- Certificate of Analysis(Lot No. 699800P-1MG-A-029and 5086PGA029)
- Certificate of Analysis(Lot No. 699800P-5MG-A-029and 5086PHA029)
- Certificate of Analysis(Lot No. 699800P-5MG-B-029and 5086PHB029)
- Certificate of Analysis(Lot No. 699800P-5MG-B-029and 5086PHB029)
- Certificate of Analysis(Lot No. 699800P-25MG-A-029and 5086PJA029)
- Certificate of Analysis(Lot No. 699800P-1MG-C-029and 5086PGC029)
- Certificate of Analysis(Lot No. 699800P-5MG-C-029and 5086PHC029)
- Certificate of Analysis(Lot No. 699800P-25MG-B-029and 5086PJB029)
- Certificate of Analysis(Lot No. 699800P-25MG-C-029and 5086PJC029)
- Certificate of Analysis(Lot No. 699800P-1MG-D-029and 5086PGD029)
- Certificate of Analysis(Lot No. 699800P-5MG-D-029and 5086PHD029)
- Certificate of Analysis(Lot No. 699800P-CONF-A-029and 5086PWA029)
- Certificate of Analysis(Lot No. 699800P-CONF-B-029and 5086PWB029)
- Certificate of Analysis(Lot No. 699800P-5MG-E-029and 5086PHE029)
- Certificate of Analysis(Lot No. 699800P-1MG-E-029and 5086PGE029)
- Certificate of Analysis(Lot No. 699800P-CONF-C-029and 5086PWC029)
- Certificate of Analysis(Lot No. 699800P-1MG-B-029and 5086PGB029)
- Certificate of Analysis(Lot No. 699800P-1MG-G-029and 5086PGG029)
- Certificate of Analysis(Lot No. 699800P-1MG-F-029and 5086PGF029)
- Certificate of Analysis(Lot No. 699800P-1MG-H-029and 5086PGH029)
- Certificate of Analysis(Lot No. 699800P-5MG-G-029and 5086PHG029)
- Certificate of Analysis(Lot No. 699800P-1MG-A-031and 5086PGA031)
- Certificate of Analysis(Lot No. 699800P-5MG-A-033and 5086PHA033)
- Certificate of Analysis(Lot No. 699800P-5MG-A-032and 5086PHA032)
AvantiPolarLipids公司是美国著名的磷脂类产品的生产商，该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供1000种以上脂类产品，由于其产品的高纯度而享誉全球。40年来，AvantiPolarLipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大，其纯度之高也是无人能及。 AvantiPolarLipids,Inc.,hasalonghistoryof50yearscreatingthehighestpuritylipidsavailable.Ourpassionforhighqualityanduniqueproductsisonlyexceededbyourexcellentreputationinthemarketplace. Althoughweareknownforourlipids,weareMorethanLipids.Weoffersolutionsfortheentireproductcycle…ResearchtoCommercialization. AvantiPolarLipids公司的主要产品和服务包括：（1）ResearchProductsHighestPurityLipidReagents（2）cGMPManufacturingAPI&ContractManufacturing（3）AdjuvantsImmunotherapy&VaccineDevelopment（4）AnalyticalServicesLipidAnalysis（5）LipidomicsMassSpecStandards,Antibodies&LipidToolbox（6）Formulationsliposomes&Nanoparticles（7）EquipmentLiposomeProductionTools（8）CustomServicesSynthesis&Beyond
AvantiPolarLipids是美国著名的磷脂类产品的生产商，该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供1000种以上脂类产品，由于其产品的高纯度而享誉全球。40年来，AvantiPolarLipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大，其纯度之高也是无人能及。
AvantiPolarLipidsInc,是美国著名的磷脂类产品的生产商，该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至百公斤级的磷脂类和甾体类中间体和试剂。主要产品Naturalsphingolipids天然鞘脂类Naturalphospholipids天然磷脂类Naturallipidsbyextraction天然提取脂类Referencestandards相关标准品Syntheticsphingolipids合成鞘脂类--Sphingosines&S-1-P鞘氨醇和鞘氨醇-1-磷酸盐--Ceramides神经酰胺--Sphingomyelins鞘磷脂--Sphingosine&ceramidederivatives鞘氨醇及神经酰胺衍生物--Sphinganine&derivatives鞘氨醇及其衍生物--C17sphingolipids十七碳鞘脂类--C20sphingolipids二十碳鞘脂类--Phytosphingosine&derivatives植物鞘氨醇及其衍生物Syntheticlipids&phospholipids合成脂质与磷脂--PC卵磷脂--PA磷脂酸--PE脑磷脂--PG磷脂酰甘油--PS磷脂酰丝氨酸--PI,PIP2&PIP3磷脂酰肌醇，磷脂酰肌醇-4,5-二磷酸，磷脂酰-3,4,5-三磷酸--CA胆酸--LysoPC溶源性卵磷脂--LysoPA溶源性磷脂酸--LysoPAAnalogues溶源性磷脂酸类似物--Lysobio-PA溶源性双磷脂酸--LysoPE,PG&PS溶源性脑磷脂，磷脂酰甘油和磷脂酰丝氨酸--AlkylPC烷基卵磷脂--Diether&Diphytanoyletherlipids二醚与二植烷醚脂质--PAF血小板活化因子--AcylPAFAnalog酰化血小板活化因子类似物--Brominatedphosphocholines溴代胆碱磷酸--Alkylphosphatederivatives烷基磷酸盐衍生物--Plasmalogen缩醛磷脂--Functionalizedlipids功能性脂类--Biotinylatedlipids生物素酰化脂质--Bioactivelipids生物活性脂类Syntheticphospholipids合成磷酸--AcylcoenzymeA乙酰辅酶A--Metabolicintermediates代谢中间产物--Adhesivelipid粘合脂质--pHsensitivelipids酸度计用脂质Transfectionreagents转染试剂Sterolderivatives甾酮衍生物Lipidblends混合脂质Glycosylatedphospholipids糖化磷脂Fluorinatedphospholipids氟化磷脂Chelators螯合剂Pre-mixedlipidsforbicelleformation构型分析用预混合脂质Diacylglycerols&analogues甘油二酯与类似物Deuteriumlabeledlipids氘标记脂质C13PC碳-13标记卵磷脂DoxylPC自旋标记卵磷脂TempoPCTempo（4-氧-4-羟-四甲基呱啶氮氧自由基）标记卵磷脂Fluoresecentsphingolipids荧光标记鞘脂类--Omegalabeled欧米加标记物--Fattyacidlabeled脂肪酸标记物Fluoresecentcholesterol荧光标记胆固醇Fluoresecentphospholipids荧光标记磷脂--Fattyacidlabeled脂肪酸标记物--Headgrouplabeled首基标记物Polymerizablelipids聚合脂质Poly（Ethyleneglycol）-lipidconjugates共轭聚脂质FunctionalizedPEGlipids功能PEG脂质Analyticalservices分析服务Drugdeliveryproduct药物运送载体Bulklipidsforpharmaceuticalproduction工业级脂质Equipment设备
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
在兔子上研究肝脏脂代谢，不知道什么细胞株合适，自己培养的担心不靠谱，不知道有没有做过这方面的，给提一些意见，感谢！
1.我利用微乳法制备SLN，模型药物、三棕榈酸甘油酯、甘油、泊洛沙姆188，80度下融化，混合均匀，2000rpm搅拌状态下滴加1%PVA水相。冷却至室温时，表面有一层脂质析出。不断增加Lipid：surfacant的比例，当达到1:20时，当冷却至室温时，仍有脂质析出。
新人一枚，想问下各位大侠，有什么好的解决方案不？
